In patients without germline or somatic BRCA1/2 mutations in recurrence setting, the Personalised Medicine Commission recommends testing the other HRD and other ovarian cancer risk genes to identify patients eligible for clinical trials and cancer genetic counselling in the relatives. This evidence concerns the gene BRCA1 and ovarian carcinoma.